Pegylated interferon-induced immune-mediated hepatitis post-liver transplantation.
A 55-year-old Caucasian male developed a well characterized autoimmune hepatitis after completing treatment with pegylated interferon and ribavirin for recurrent hepatitis C. We hypothesize that pegylated interferon triggered a severe form of immune-mediated hepatitis.
Kontorinis
Nickolas
N
Division of Liver Diseases, Recanati-Miller Transplantation Institute, New York, NY 10029, USA. nickolas.kontorinis@mssm.edu
Agarwal
Kaushik
K
Elhajj
Nassim
N
Fiel
M Isabel
MI
Schiano
Thomas D
TD
D000998:Antiviral Agents / Q000009:adverse effects*; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy*; D019693:Hepatitis, Autoimmune / Q000209:etiology*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D008103:Liver Cirrhosis / Q000601:surgery; D016031:Liver Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000009:adverse effects*; D011994:Recombinant Proteins
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C100416:peginterferon alfa-2a